Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3475-3481

  Hsu, Nan Yung ^a,b   Wu, Jeng Yuan ^b   Liu, Xiyong ^c   Yen, Yun ^c   Chen, Chih Yi ^d   Chou, Ming Chih ^a,e   Lin, Chun Hsuan ^f   Lee, Huei ^a,e   Cheng, Ya Wen ^a,e  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b Buddhist General Tzu Chi Hospital   (Taiwan)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^f NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

hRRM2; Non small cell lung cancer; p53R2; Ribonucleotide reductase

Indexed keywords

BIOLOGICAL MARKER; P53 DEPENDENT RIBONUCLEOTIDE REDUCTASE SMALL SUBUNIT; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TUMOR DIFFERENTIATION;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTEIN SUBUNITS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80054722409     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Montain CF: Revison in the international system for staging lung cancer. Chest 111(6): 1710-1717, 1977.
2. WHO: The World Health Organization. Histological typing of lung tumors. Am J Clin Pathol 77: 123-136, 1982.
3. Reichard P: Ribonucleotide reductases: the evolution of allosteric regulation, Arch Biochem Biophy 397(2): 149-155, 2002.
4. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, Takei Y and Nakamura Y: Ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 404(6773): 42-49, 2000. (Pubitemid 30143125)
5. Jorderin LP, Seve P, Tredon O and Dumontet C: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. Lancet Oncol 14, 2010.
6. Fan H, Huang A, Villegas C and Wright JA: The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments. Proc Natl Acad Sci USA 94(24): 13181-13186, 1997.
7. Chang CH and Cheng YC: Substrate specificity of human ribonucleotide reductase from Molt-4F cells. Cancer Res 39(12): 5081-5086, 1979. (Pubitemid 10163119)
8. Heidel JD, Liu JYC, Yen Y, Zhou B, Heale BS, Rossi JJ, Bartlett DW and Davis ME: Potent siRNA inhibitors of ribonucleotide reductase subunit RRM2 reduce cell proliferation in vitro and in vivo. Clin Cancer Res 13(7): 2207-2205, 2007.
9. Duxbury MS and Whang EE: RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness. Biochem Biophys Res Commun 354(1): 190-196, 2007. (Pubitemid 46123218)
10. Zhang K, Hu S, Wu J, Lu J, Wang X, Liu X, Zhou B and Yen Y: Overexpression of RRM2 decreases thrombspondin-1 and increases VEGF production in human cancer cells in vitro and in vivo: implication of RRM2 in angiogenesis. Mol Cancer 8: 11, 2009.
11. Liu X, Zhou B, Xue L, Yen F, Chu P, Un F and Yen Y: Ribonucleotide reductase subunits M2 and p53R2 are potential biomarkers for metastasis of colon cancer. Clin Colorectal Cancer 6(5): 374-381, 2007. (Pubitemid 46340204)
12. Souglakos J, Boukovinas I, Taron M, Mendez P, Mavroudis D, Tripaki M, Hatzidaki D, Koutsopoulos A, Stathopoulos E, Georgoulias V and Rosell R: Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel gemcitabine. Br J Cancer 98(70): 1710-1715, 2008. (Pubitemid 351684679)
13. Shao J, Zhou B, Zhu L, Qiu W, Yuan YC, Xi B and Yen Y: In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res 64(1): 1-6, 2004. (Pubitemid 38114072)
14. Guittet O, Hakansson P, Voevodskaya N, Fridd S, Gräslund A, Arakawa H, Nakamura Y and Thelander L: Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the Rl protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276(44): 40647-40651, 2001.
15. Nakan OK, Balint E, Ashcroft M and Vousden KH: A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 19(37): 4283-4289, 2000.
16. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, and Arakawa H: p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 61(22): 8256-8262, 2001. (Pubitemid 33091620)
17. Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, Mudryj M and deVere White RW: Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res 6(5): 808-818, 2008.
18. Fan H, Villegas C and Wright JA: Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 93(24): 14036-13040, 1996.
19. Liu X, Zhou B, Xue L, Shih J, Tye K, Lin W, Qi C, Chu P, Un F, Wen W and Yen Y: Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells. Clin Cancer Res 12(21): 6337-6344, 2006. (Pubitemid 44799702)
20. Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, Lee H and Cheng YW: p53R2 expression as a prognostic biomarker in early stage non-small cell lung cancer. Oncol Lett 1: 609-614, 2010.
21. Bepler G, Olaussen KA, Vataire AL, Soria JC, Zheng Z, Dunant A, Pignon JP, Schell MJ, Fouret P, Pirker R, Filipits M and Brambilla E: ERCC1 and RRM1 in the International Adjuvant Lung Trial by automated quantitative in situ analysis. Am J Pathol 178(1): 69-78, 2011.
22. Kretschmer C, Sterner-Kock A, Siedentopf F, Schoenegg W, Schlag PM and Kemmner W: Identification of early molecular markers for breast cancer. Mol Cancer 10(1): 15, 2011.
23. Morikawa T, Maeda D, Kume H, Homma Y and Fukayama M: Ribonucleotide reductase M2 subunit is a novel diagnostic marker and a potential therapeutic target in bladder cancer. Histopathology 57(6): 885-892, 2010.
24. Fujita H, Ohuchida K, Mizumoto K, Itaba S, Ito T, Nakata K, Yu J, Kayashima T, Souzaki R, Tajiri T, Manabe T, Ohtsuka T and Tanaka M: Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12(10): 807-817, 2010.
25. Toffalorio F, Giovannetti E, De Pas T, Radice D, Pelosi G, Manzotti M, Minocci D, Spaggiari L, Spitaleri G, Noberasco C, Catania C, Boselli S, Danesi R and de Braud F: Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. Pharmacogenomics J 10(5): 180-190, 2010.
26. Zheng Z, Chen T, Li X, Haura E, Sharma A and Bepler G: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 356(8): 800-808, 2007. (Pubitemid 46294612)
27. Månsson E, Flordal E, Liliemark J, Spasokoukotskaja T, Elford H, Lagercrantz S, Eriksson S and Albertioni F: Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. Biochem Pharmacol 65(2): 237-247, 2003. (Pubitemid 36015826)
28. Wang X, Zhenchuk A, Wiman KG and Albertioni F: Regulation of p53R2 and its role as potential target for cancer therapy. Cancer Lett 276(1): 1-7, 2009.
29. Boukovinas I, Papadaki C, Mendez P, Taron M, Mavroudis D, Koutsopoulos A, Sanchez-Ronco M, Sanchez JJ, Trypaki M, Staphopoulos E, Georgoulias V, Rosell R and Souglakos J: Tumor BRCAl, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small cell lung cancer patients. PLoS One 3(11): e3695, 2008.
30. Furata E, Okuda H, Kobayashi A and Watabe K: Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 1805(2): 141-152, 2010.
31. Xu X, Page JL, Surtees JA, Liu H, Lagedrost S, Lu Y, Bronson R, Alani E, Nikitin AY and Weiss RS: Weiss, Broad overexpression of ribonucleotide reductase genes in mice specificy induces lung neoplasms. Cancer Res 68(8): 2652-2560, 2008.
32. Uramoto H, Sugio K, Oyama T, Hanagiri T and Yasumoto K: P53R2, p53- inducible ribonucleotide reductase gene, correlated with tumor progression of non-small cell lung cancer. Anticancer Res 26(2A): 983-988, 2006.
33. Piao C, Lin M, Kim HB, Lee SM, Amatya PN, Hyun JW, Chang IY and You HJ: Ribouncleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. Oncogene 28(21): 2173-2184, 2009.
34. Okumura H, Natsugoe S, Yokomalura N, Kita Y, Matsumoto M, Uchikado Y, Setoyama T, Owaki T, Ishigami S and Aikou T: Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma. Clin Cancer Res 12(12): 3740-3744, 2006.
35. Yanamoto S, Kawasaki G, Yamada S, Yoshitomi I, Yoshida H, and Mizuno A: Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. Oral Oncol 45(6): 521-525, 2009.
36. Fan H, Villegas C, Huang A, and Wright JA: The mammalian ribonucleotide reductase R2 compnent cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 58(8): 1650-1653, 1998. (Pubitemid 28215087)
37. Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, Shih J and Yen Y: Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 16(1): 43-49, 1998. (Pubitemid 28122554)